Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Mar;26(3):1272–1279. doi: 10.1096/fj.11-184556

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© FASEB

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/us/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — Magnitude and kinetics of antigen-specific immune responses are comparable following immunization with alum or CpG adjuvants. A) All adjuvants significantly increased the mean percentage of tg T cells (CD4⁺KJ1.26⁺) expressing CD69, at d 1, 5, and 11. B) Mean percentage of tg T cells at the peak of expansion at d 5 postimmunization. C) Total number of tg T cells expressing the IL-4 reporter was higher early (d 1; P<0.05) with CpG/OVA compared with alum/OVA, although later (d 11) only alum/OVA or alum/OVA/CpG produced significant numbers of GFP-positive antigen-specific cells compared with nonimmunized controls. D, E) Serum was taken from animals 14 d after immunization and assessed for the presence of anti-OVA IgG1 (D) and anti-OVA IgG2a (E) by ELISA. Results are means ± sd of 3 animals/group and are representative of ≥2 independent experiments. *P < 0.05 vs. unimmunized control; 1-way ANOVA.